Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria shifts after bariatric surgery: a clue to better weight loss?

NCT ID NCT07277465

Knowledge-focused Sponsor: Celia Bañuls Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 60 obese patients who had bariatric surgery (like gastric bypass or sleeve gastrectomy). Researchers checked their gut bacteria and hormone levels before and 6-12 months after surgery. The goal was to see how the microbiome changes and if those changes relate to metabolic health or sex.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bariatric surgery (gastric bypass, sleeve gastrectomy, or SADI-S)
What this could lead to
If successful, this could reveal how gut bacteria affect weight loss and metabolic health after bariatric surgery, pointing toward future microbiome-based treatments for obesity.
What could go wrong
This is a small, completed observational study with no treatment being tested, so results may not apply broadly. It only looks at changes, not whether those changes cause health improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2021

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a body mass index (BMI) greater than 40 kg/m² (or \> 35 kg/m² with minimum one obesity comorbidity). * Aged between 18 and 65 years. * Patients with a known duration of obesity exceeding five years, despite dietary interventions and farmacological treatment. Exclusion Criteria: * Due to the nature of the study, patients with acute or chronic inflammatory diseases, established hepatic or renal insufficiency (defined as transaminase levels ±2 SD from the mean and estimated glomerular filtration rate \[CKD-EPI formula\] \>60), neoplasic diseases, or secondary causes of obesity (e.g., hypothyroidism, Cushing's syndrome) will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese patients with bariatric surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese patients with bariatric surgery

Contacts and locations

Locations

  • FISABIO

    Valencia, 46017, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.